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Abstract
Introduction: The aim of the study was to evaluate the clinical outcome of intensity modulated radiotherapy
(IMRT) in 46 patients with paranasal sinus tumors with special respect to treatment-related toxicity.
Patients and methods: We treated 46 patients with histologically proven tumors of the paranasal sinuses with
IMRT. Histological classification included squamous cell carcinoma in 6, adenocarcinoma in 8, adenoidcystic
carcinoma in 20 and melanoma in 8 patients, respectively.
Six patients had been treated with RT during initial therapy after primary diagnosis, and IMRT was performed for
the treatment of tumor progression as re-irradiation.
Results: Overall survival rates were 96% at 1 year, 90% at 3 years.
Calculated from the initiation of IMRT as primary radiotherapy, survival rates at 1 and 3 years were 95% and 80%.
In six patients IMRT was performed as re-irradiation, and survival rate calculated from re-irradiation was 63% at
1 year.
Local control rates were 85% at 1, 81% at 2 and 49% at 3 years after primary RT and 50% at 1 year after re-
irradiation.
Distant metastases-free survival in patients treated with IMRT as primary RT was 83% after 1 and 64% after 3
years. For patients treated as primary irradiation with IMRT, the distant control rate was 83% at 1 year and 0%
at 2 years.
No severe radiation-induced side-effects could be observed.
Conclusion: IMRT for tumors of the paranasal sinuses is associated with very good tumor control rates.
Treatment-related acute and long-term toxicity can be minimized as compared to historical results with
conventional RT.
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Introduction
Tumors of the paranasal sinuses (PNS) and nasal cavity
are relatively rare, accounting for about 3–5% of all head
and neck tumors; they are commonly associated with a
poor prognosis [1,2]. Their incidence amounts to about
0.5% of all malignant diseases, and they show a wide vari-
ety of histologic subtypes [3]. The presence of air filled
spaces permits silent growth of these tumors, and symp-
toms often occur only after the tumor has reached a con-
siderable volume. Therefore, the majority of patients
presents with advanced tumors, often extending into the
skull base in close vicinity to sensitive risk structures such
as optic nerves, chiasm, eyes and brain stem [4-6].
The primary treatment of choice is an aggressive surgical
approach, followed by postoperative radiotherapy (RT)
[7,8]. Due to the complexity of the anatomy and the prox-
imity of these neoplasms to critical normal tissue struc-
tures radical surgery is often not possible [9-14];
furthermore, RT is associated with a high risk of treat-
ment-related toxicity [15-17]. In the past, chronic toxicity
to the optic system was of major concern, with RT-
induced blindness rates of up to 37% [17-19]. Further-
more, underdosage in regions of risk were a major con-
cern with conventional RT techniques.
With modern high-precision RT-techniques such as Inten-
sity Modulated Radiotherapy (IMRT), it is possible to
increase the dose to defined target volume while reducing
the dose to limiting organs at risk (OAR) to preserve organ
function and subsequently quality of life. Furthermore, it
is possible to improve dose conformality to the target vol-
ume with this technique as compared to conventional
conformal RT techniques.
Previous clinical results published from our institution
have shown that IMRT can be applied safely and effec-
tively in patients with tumors of the PNS [20]. However,
these results were confined to a small number of patients
only with a short follow-up time.
The present study retrospectively evaluates the results of
IMRT in 46 patients with carcinomas of the PNS, with spe-
cial respect to treatment related acute and chronic toxicity.
Patients and methods
Patients' characteristics
Between January 1999 and October 2005, we treated 46
patients with histologically proven tumors of the PNS
with IMRT. All patients were followed regularly after treat-
ment.
Patients' characteristics are summarized in table 1. Histo-
logical classification included squamous cell carcinoma
(SCC) in 6, adenocarcinoma (AC) in 12, adenoidcystic
carcinoma (ACC) in 20 and melanoma in 8 patients.
Patients with benign tumors such as inverted papilloma
and with palate or skin primary tumors with secondary
invasion of the sinuses and the nose were excluded from
the analysis. Accordingly, pediatric sarcomas and esthe-
sioneuroblastomas invading the PNS were not included.
The tumor site was determined from the epicenter of the
disease, as determined at the time of diagnosis or, more
rarely, from an analysis of the clinical, radiologic or oper-
ative data. The sub site of origin was the maxillary sinus in
22 patients, the sphenoid sinus in 4, the ethmoidal sinus
in 4 patients, and the nasal cavity in 16 patients, respec-
tively. All patients were staged according to the 2002 TNM
classification system [21]. Five patients presented with T1/
T2 tumors, 11 with T3 and 30 patients with T4 tumors,
respectively.
Six patients (13%) presented with intracranial invasion of
the tumor; in 11 patients (24%) the orbit was infiltrated.
Six out of 46 patients (13%) had been treated with RT dur-
ing initial therapy after primary diagnosis, and IMRT was
performed as re-irradiation for the treatment of tumor
progression.
Table 1: Patient and disease characteristics of 46 patients with 
paranasal sinus carcinomas treated with IMRT
N (%)
Gender
female 18 (39%)
male 28 (61%)
Histology
Adenocarcinoma 8 (17.4%)
Squamous Cell Carcinoma 6 (13%)
Adenoid-cystic Carcinoma 20 (43.4%)
Melanoma 8 (17.4%)
other 4 (8.8%)
Primary tumor site
Maxillary sinus 22 (47.8%)
Ethmoidal sinus 4 (8.7%)
Sphenoid sinus 4 (8.7%)
Nasal cavity 16 (34.8%)
Tumor stage
T1 2 (4%)
T2 3 (7%)
T3 11 (24%)
T4 30 (65%)
Nodal stage
N0 34 (74%)
N1 6 (13%)
N2 1 (2%)
Nx 5 (11%)Radiation Oncology 2006, 1:23 http://www.ro-journal.com/content/1/1/23
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Treatment planning
All patients were treated with IMRT using the step-and-
shoot approach [22]. For treatment planning, patients
were fixed in an individually manufactured precision
head mask made of Scotch cast® (3 M, St.Paul, Minneapo-
lis, MN), allowing a treatment setup accuracy of 1–2 mm
[23]. If treatment of the lymph nodes was required
patients were additionally positioned with an individu-
ally fixed vacuum pillow in order to immobilize the neck
and thorax. With this immobilization system attached to
the stereotactic base frame, we performed contrast-
enhanced CT- and MRI-images under stereotactic condi-
tions, with a slice thickness of 3 mm. We scanned the
whole treatment region with a superior and inferior mar-
gin of at least 3 cm.
After stereotactic image fusion based on the localizer-
derived coordinate system [24,25], all critical structures
including the optic nerves, chiasm, brainstem and eyes as
well as the target volumes were defined on each slice of
the three-dimensional data cube. The Gross Tumor Vol-
ume (GTV) was defined as the macroscopic tumor visible
on CT- and MRI-scans. For the clinical target volume
(CTV) a generous margin was added according to the typ-
ical pathways for microscopic spread and the anatomical
relationship of adjacent structures. Generally, the CTV
consisted of the resection cavity, all PNS completely or
partially invaded, adding a safety margin of 3–5 mm. No
elective RT of the cervical lymph nodes was performed. If
treatment of the local lymph nodes was necessary, they
were defined as a part of the CTV.
Inverse treatment-planning was performed using the Kon-
Rad software developed at the German Cancer Research
Center (dkfz), which is connected to the 3D planning pro-
gram VIRTUOS to calculate and visualize the 3D dose dis-
tribution. With the KonRad planning programme, dose
constraints and penalties for the target volumes as well as
the organs at risk must be defined prior to starting the
optimization process. The couch, gantry and collimator
angles as well as the number of beams and intensity levels
can be varied. Treatment planning has been described in
detail previously [20,26-28].
Treatment was delivered by a Siemens accelerator
(Primus, Siemens, Erlangen, Germany) with 6 or 15 MV
photons using an integrated motorized multileaf collima-
tor (MLC) for the step-and-shoot technique automatically
delivering the sequences.
The total doses were prescribed to the median of the target
volume, meaning 50% of the target volume receives 100%
of the dose. The median target volume was chosen for
dose prescription since is represents the majority of the
defined target volume.
For dose prescription we adhered to the tolerance doses of
each organ at risk; dose constraints were set at 27 Gy for
the parotid, 54 Gy for the optic nerves, chiasm and brain
stem and 45 Gy for the spinal cord. Dose prescription was
performed, with respect to these tolerance doses, after
plan calculation and analyses of the dose volume histo-
gram (DVH). A summary of the DHV data is provided in
table 2.
For patients treated with IMRT as adjuvant RT after sur-
gery, the median total dose applied was 64 Gy in a median
fractionation of 2 Gy (range 1.8 – 2.2 Gy). A median total
dose of 54 Gy was prescribed to the CTV, and a median
dose of 64 Gy was prescribed to the GTV as a boost. For
irradiation of the lymph nodes, a median dose of 54 Gy
was applied.
In 6 patients IMRT was performed as re-irradiation with a
median dose of 46 Gy in a median fractionation of 2 Gy
(range 1,8 Gy – 2 Gy). Prior to IMRT, a median total dose
of 62 Gy had been applied using conventional RT.
Table 2: Summary of the DVH-data
Characteristics Mean SEM Median Range
Boost(CTV)
Dmed (Gy) 66 12,4 66 36–78
V>30% (%) 99,97 0,08 100 99,7–100
V<90% (%) 8,18 18,5 4,3 0,4–100
Volume (cm3) 177,8 102,93 153,7 26,5–402,4
PTV
Dmed (Gy) 56,8 12,4 60 23,6–67,5
V>30% (%) 99,91 0,37 100 98–100
V<90% (%) 25,8 20,15 21,3 1,7–70,4
Volume (cm3) 475,6 380,8 342,2 34–1524
Right Optic Nerve
Dmed (Gy) 35,5 11,47 37,9 9,3–62,5
V>30% (%) 93,98 13,8 100 35,3–100
V<90% (%) 90,93 23,3 100 13,4–100
Volume (cm3) 1,3 0,42 1,4 0,5–2,4
Left Optic Nerve
Dmed (Gy) 34,39 11,52 37,4 13,2–60,5
V>30% (%) 89,9 20,01 100 10–100
V<90% (%) 92,2 21,75 100 14,4–100
Volume (cm3) 1,2 0,48 1,2 0,5–2,2
Chiasm
Dmed (Gy) 24,79 8,4 25,3 9,4–41,4
V>30% (%) 72,88 31,56 83,05 0–100
V<90% (%) 97,52 25,66 100 0,96–100
Volume (cm3) 1,5 0,6 1,56 0,2–2,9
Brain Stem
Dmed (Gy) 24,9 9,95 25,2 9,9–63,2
V>30% (%) 66,5 24,95 70,7 0,6–100
V<90% (%) 99,9 0,19 100 99,1–100
Volume (cm3) 27,5 5,35 12,8 12,8–35,2Radiation Oncology 2006, 1:23 http://www.ro-journal.com/content/1/1/23
Page 4 of 8
(page number not for citation purposes)
Follow-up
All patients were followed prospectively after RT. A thor-
ough clinical assessment including contrast-enhanced
MRI- or CT-scans as well as an ultrasound were scheduled
6 weeks after completion of RT, then in 3-months inter-
vals for the first year. Thereafter, follow-up visits were
scheduled every 6 months or as needed clinically. Addi-
tionally, patients were followed by otorhinolaryngologist
as well as ophthalmologist on a regular basis.
Acute and late therapy-related side effects were scored
according to the Common Toxicity Criteria (CTC) version
3.0 of the U.S. National Institutes of Health.
Statistics
Local tumor control, distant-metastases-free survival, sur-
vival from RT as well as overall survival were determined
using the Kaplan-Meier-Method [29], calculated from the
initiation of RT. Overall survival was defined as the sur-
vival time calculated from the primary diagnosis of the
PNS tumor. Survival from IMRT was calculated as the sur-
vival time starting from the initiation of IMRT. All analy-
ses were performed using the Statistica software (StatSoft
6.0, Germany).
Results
Treatment in general
A typical IMRT treatment plan is depicted in Fig. 1. The
main goal was optimal sparing of the optic structures as
well as the brain stem, without compromising the dose
conformality to the CTV and PTV. A summary of the DVH-
data can be found in table 2.
Overall survival
The median follow-up time was 16 months (range 3–40
months).
Typical IMRT treatment plan of a patient treated for paranasal sinus carcinoma: transversal view (A), sagital view (B) and coro- nar view (C). Figure 1
Typical IMRT treatment plan of a patient treated for paranasal sinus carcinoma: transversal view (A), sagital view (B) and coro-
nar view (C).Radiation Oncology 2006, 1:23 http://www.ro-journal.com/content/1/1/23
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Nine patients died of tumor progression during follow-
up. Thirty-seven patients were alive at the time point of
analysis. Overall survival rates were 96% at 1 year. Tumor
stage, histology, primary site of origin and the presence of
orbital and intracranial invasion did not influence overall
survival; however, numbers of patients in each subdivi-
sion might be too small to reach statistical significance.
No treatment-related deaths occurred.
Survival after IMRT
Calculated from the initiation of IMRT as adjuvant radio-
therapy, survival rates at 1 year was 95% (Fig. 2A).
In six patients IMRT was performed as re-irradiation, and
survival rate calculated from re-irradiation was 63% at 1
year (Fig. 2A).
Primary site of origin, presence of orbital or intracranial
invasion, histological subtype and tumor stage did not
influence survival after primary irradiation or re-irradia-
tion significantly, most probably due to the small number
of patients in each subgroup.
Local control
In patients were IMRT was performed as adjuvant RT,
local control rates were 85% at 1 and 81% at 2 years,
respectively (Fig. 2B). Local control after IMRT performed
as re-irradiation was 50% at 1 year. We could not identify
any significant prognostic factors for local tumor control
including histology, tumor stage, intracranial and orbital
extension of the tumor and primary site of origin. Again,
this could be due to the relatively small number of
patients within each subclassification.
Distant tumor control
Distant metastases-free survival in patients treated with
IMRT as adjuvant RT was 83% after 1 year (Fig. 3).
For patients treated as re-irradiation with IMRT, the dis-
tant control rate was 83% at 1 year and 0% at 2 years.
No prognostic factors for distant metastases-free survival
could be found (Table 3).
Acute and chronic toxicity
Minor acute side effects of RT included focal alopecia,
nausea/vomiting and fatigue.
The development of severe radiation-induced side-effects
could be prevented in our study group. Mucositis devel-
oped in most patients, however, Grade 2 and 3 mucositis
developed in 8 and 2 patients only. No Grade IV reactions
to the mucosa could be observed. Skin erythema devel-
oped in 28 patients, in 19 as CTC grade I and 9 as CTC
grade II. No grade III and IV erythema could be observed.
Radiation-induced conjunctivits developed in 12 patients
as CTC grade I and in 1 as CTC grade II. No radiation-
induced visual deficits could be observed. All patients
were seen and the side effects documented by an ophthal-
mologist.
During follow-up, 19 patients presented with mild xeros-
tomia (CTC grade I) and 2 patients with CTC grade II. No
severe (CTC grade III and IV) xerostomia could be
observed.
No other severe side effects could be observed.
Survival calculated from the initiation of IMRT (A). Figure 2
Survival calculated from the initiation of IMRT (A). Local pro-
gression-free survival calculated from the initiation of IMRT 
(B).Radiation Oncology 2006, 1:23 http://www.ro-journal.com/content/1/1/23
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Discussion
The management of PNS cancers remains a major chal-
lenge in oncology. A major problem in patients with car-
cinomas of the PNS is that most tumors are highly
advanced at the time point of diagnosis. Commonly, early
symptoms differ little from ordinary nasal complaints,
and their temporary regression by antibiotics misleads
both the patients and the physicians [30-32]. Thereafter, if
symptoms recur or should more alarming symptoms such
as visual defects, cranial nerve deficits or a visible mass in
the head-and-neck area develop, tumor stage is com-
monly T3 or T4, with outcome tending to be less favoura-
ble [33]. Most probably, the presence of large air spaces
and the fast growth pattern of the most common histolo-
gies allow the fast and asymptomatic expansion of PNS
carcinomas. Tumor volumes, even after complete surgical
resection of the tumor, are therefore relatively large, in the
majority of cases affecting all sinuses.
Until now, there is substantial controversy as to which
treatment can be considered the "standard treatment
approach": surgery, definitive radiotherapy or a combined
multimodality approach including surgical resection fol-
lowed by postoperative surgery. For single-modality ther-
apies, outcome is generally poor. Amendola et al. reported
on 39 patients treated with curative intent with resection
or definitive RT and found no statistically significant dif-
ferences in survival at 3 and 5 years, with a 5 year survival
rate of 31% and 35% for resection and RT, respectively
[34]. A number of reports have demonstrated some
improvement in outcome with combined modality ther-
apy. St. Pierre and Baker reported on 61 patients treated
with surgical resection alone, definitive RT or combined
treatment, showing a clear benefit for patients receiving
combined surgery and RT [35]. Paulino and colleagues
could show in a group of 48 patients that local control
and disease-specific survival rates at 5 years were signifi-
cantly increased in the group receiving surgery and RT as
compared to RT alone, with an overall survival rate of
52% and 0%, respectively [36]. Blanco et al. demonstrated
that disease-free survival increased slightly with a multi-
modality treatment approach, however, overall survival
was unaltered [37]. In our group all patients were treated
with IMRT, in 6 patients IMRT was performed as re-irradi-
ation for tumor progression. Overall survival was 96% at
1 year. Calculated from the initiation of IMRT, survival
rates for the group treated with primary RT was 95% at 1
year. This rate is relatively high as compared to data
reported in the literature. This might be due to the high
number of patients with ACC included into this analysis,
showing a smaller rate of local and distant progression
than other histologies such as SCC, SC or Melanoma.
However, within this analysis, neither histology, nor other
common prognostic factors did significantly influence
outcome; most probably this is due to the relatively small
number of patients in each subgroup.
In the past, the main concern in the radiotherapeutic
treatment of PNS tumors was treatment-related toxicity.
The close vicinity of sensitive organs at risk such as the
eyes, optic nerves, chiasm and brain stem makes it diffi-
cult to apply a high and effective dose to the target volume
while sparing healthy tissue using conventional RT tech-
niques. A number of groups have reported unilateral and
bilateral blindness rates after conventional RT of PNS
tumors up to 60% and 10% of the patients, respectively
[38-40]. In other series, the rate for radiation-induced
blindness ranges from 15% to 40% [17-19,19,41]. How-
ever, Karim et al. showed that by applying a shrinking
technique for the target volume and thus preventing irra-
diation of the whole orbit in patients with orbital inva-
sion did not influence outcome negatively, while the
ocular structures were excluded from the high-dose
regions. However, RT-induced blindness was rare (4%)
[42,43].
The introduction of IMRT now allows application of high
doses to complex target volumes, while the surrounding
OARs can be spared and toxicity may be reduced. Over the
last years, IMRT has been implemented widely into the
clinical routine. However, most publications to date have
focused on treatment planning techniques and theoretical
plan comparisons of IMRT plans as compared to confor-
mal RT plans [5,40,44-47]. For tumors of the PNS the
potential benefits of IMRT are obvious due to the anatom-
ical site: the target volumes to be treated are in very close
vicinity to sensitive normal tissues and organs at risk
(OAR), especially the eyes, optic nerves, chiasm, brain
Distant metastases-free survival calculated from the initiation  of IMRT performed as primary irradiation (black curve) and  as re-irradiation (red curve) Figure 3
Distant metastases-free survival calculated from the initiation 
of IMRT performed as primary irradiation (black curve) and 
as re-irradiation (red curve).Radiation Oncology 2006, 1:23 http://www.ro-journal.com/content/1/1/23
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stem and spinal cord. With conventional RT techniques,
the dose application to the target volumes is limited by
the tolerated doses of the OAR in order to avoid high rates
of treatment-related toxicity.
Until now, only a small number of groups have reported
their results of IMRT in patients with carcinomas of the
PNS. Duthoy et al. published their results of IMRT in 39
patients with PNS cancers [48]. The median dose deliv-
ered in that study was 70 Gy, and the actuarial overall sur-
vival rates were 68% at 2 and 59% at 4 years, respectively.
The actuarial local control rates were 73% and 68% at 2
and 4 years, respectively. However, acute toxicity was
mild, and no patient developed Grade or 4 ocular toxicity.
Two patients developed decreased vision after RT, how-
ever, no RT-induced blindness was observed. Our results
are in good accordance with these data.
The development of severe radiation-induced side-effects
could be prevented in our study group as well. Mucositis
developed in most patients, however, Grade 2 and 3
mucositis developed in 8 and 2 patients only. No Grade
IV reactions to the mucosa could be observed. A signifi-
cant number of patients developed ocular side effects,
however, no Grade 3 and 4 reactions occurred, especially,
no RT-induced blindness. However, follow-up time still
remains relatively short.
The results of the present study therefore confirm the idea
that IMRT can lead to equal local control and survival
rates as compared to conventional or conformal RT in
patients with carcinomas of the PNS. However, with
IMRT, OARs in close vicinity to the target volume can be
spared effectively. Thus, the risk of severe treatment
related side effects especially to the optic system can be
minimized.
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